Our Mission

The Consortium brings together international pediatric gastroenterologists and scientists from academic centers to identify the causes of Very Early Onset Inflammatory Bowel Disease (VEO-IBD) in order to develop new treatments for children with these rare diseases.

Our Strategy

In order to understand the molecular basis of VEO-IBD and to develop individualized treatments, we established the international interdisciplinary Very Early Onset Inflammatory Bowel Disease (VEO-IBD) Consortium, comprising 13 leading experts in the fields of basic and clinical research.

The VEO-IBD Consortium partners with over 100 clinical and academic centers worldwide and fosters collaborative interactions with its members in order to facilitate diagnosis and develop treatment strategies.

Our Research


Patient enrollment enables us to:

  • Identify the genetic variants responsible for VEO-IBD and define the molecular networks which are disrupted as a result of these variants.
  • Create an innovative Pediatric VEO-IBD Portal for Personalized Patient Care (P4Care) to develop tailored treatments for VEO-IBD patients.
  • Determine environmental factors affecting genetic and immunologic pathways relevant to VEO-IBD.

Founding Members

Principal Investigators

Aleixo Muise, MD, PHD

  • Co-Director, IBD Centre
  • Staff Clinician – Scientist
    Hospital for Sick Children
    University of Toronto

Christoph Klein, MD, PHD

  • Chair, Department of Pediatrics
  • Director, Care-For-Rare Laboratories
    Dr. von Hauner Children’s Hospital
    Ludwig Maximilians University

Scott B. Snapper, MD, PHD

  • Wolpow Family Chair in IBD Treatment and Research
  • Director, IBD Center
    Boston Children’s Hospital
    Harvard Medical School

Founding Investigators

  • Judy Cho, MD

    Ruth Ward-Coleman Professor in Translational Genetics, Medicine and Gastroenterology; Vice-Chair, Genetics and Gastroenterology, Mount Sinai School of Medicine, NYC

  • Hans Clevers, MD, PhD

    Director of the Hubrecht Institute, Utrecht, The Netherlands

  • Lynn Goldman, MD

    Michael and Lori Milken Dean of Public Health, George Washington University, DC

  • Dermot McGovern, MD, PhD

    Director, Translational Medicine, Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Hospital, LA

  • Ruslan Medzhitov, PhD

    Professor of Immunobiology; Investigator, Howard Hughes Medical Institute, Yale University

  • Josef Penninger, MD

    Senior Scientist and Scientific Director, Institute of Molecular Biotechnology, Austria

  • Fiona Powrie, PhD

    Chair in Gastroenterology, Head of Nuffield Department of Medicine – Experimental Medicine, University of Oxford

  • David Relman, MD

    Professor, Department of Microbiology & Immunology, Stanford University School of Medicine, CA

  • Eric Schadt, PhD

    Chair of the Department of Genetics and Genomics Sciences, Director of the Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine, NYC

  • Dan Turner, MD, PhD

    Head of the Pediatric Gastroenterology and Nutrition Unit at Shaare Zedek Hospital, Jerusalem, Israel.

Collaboration Partners

© Copyright - VEO-IBD Consortium